Citation: | YANG Hui-fang, WANG Qun. Efficacy and Safety of Ustekinumab for Plaque Psoriasis: A Meta-Analysis[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 157-162. DOI: 10.3969/j.issn.1671-5144.2012.03.018 |
[1] |
赵辨. 中国临床皮肤病学[M]. 江苏科学技术出版社, 2009: 1008-1010.
|
[2] |
Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis[J].N Engl J Med, 2007,356(6): 580-592.
|
[3] |
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)[J]. Lancet, 2008,371(9625): 1665-1674.
|
[4] |
Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of Ustekinumab, a human interleukin-12/23 monoclonal antibody,in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)[J]. Lancet, 2008,371(9625): 1675-1684.
|
[5] |
Tsai T, Ho J, Song M, et al. Efficacy and safety of Ustekinumab for the treatment of moderate-to-severe psoriasis: A phase Ⅲ, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)[J]. J Dermatol Sci,2011,63 (3): 154-163.
|
[6] |
Product monograph. Stelara (Ustekinumab) [EB/OL]. Toronto, Ontario: Centocor Ortho Biotech Inc, December 2009.
|